Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLOSSOM: Anifrolumab in Pediatric Systemic Lupus Erythematosus
NCT05835310Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Mar 2024; status: recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05835310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835310.